Drug Profile
SGC cancer gene therapy - Cyclacel Pharmaceuticals
Latest Information Update: 18 May 2011
Price :
$50
*
At a glance
- Originator University of Glasgow
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
- 03 Mar 2006 This programme is still in active development
- 23 Apr 1998 Preclinical development for Cancer in United Kingdom (Unknown route)